

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天津泰達生物醫學工程股份有限公司

Tianjin TEDA Biomedical Engineering Company Limited

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 8189)

**CLARIFICATION ANNOUNCEMENT IN RELATION TO
THE ANNUAL RESULTS ANNOUNCEMENT
FOR THE YEAR ENDED 31 DECEMBER 2017**

Reference is made to the annual results announcement dated 26 March 2018 of Tianjin TEDA Biomedical Engineering Company Limited (the “**Company**”) for the year ended 31 December 2017 (the “**Announcement**”). Unless otherwise defined, capitalized terms used in this announcement shall have the same meaning as defined in the Announcement.

The Company would like to clarify that the table under the note headed “13. RESERVES” to the financial statements on page 18 of the Announcement shall be deleted in its entirety and be replaced as follows:

	Share premium RMB <i>(Note (i))</i>	Capital reserve RMB <i>(Note (iii))</i>	Accumulated losses RMB <i>(Note (iv))</i>	Other reserve RMB <i>(Note (v))</i>	Total RMB
The Company					
At 1 January 2016	154,667,871	(2,312,483)	(69,095,026)	(22,032,403)	61,227,959
Loss and total comprehensive income for the year	—	—	(15,004,994)	—	(15,004,994)
At 31 December 2016	154,667,871	(2,312,483)	(84,100,020)	(22,032,403)	46,222,965
Issue of new shares	100,798,343	—	—	—	100,798,343
Loss and total comprehensive income for the year	—	—	(20,878,915)	—	(20,878,915)
At 31 December 2017	<u>255,466,214</u>	<u>(2,312,483)</u>	<u>(104,978,935)</u>	<u>(22,032,403)</u>	<u>126,142,393</u>

The above clarification does not affect other information contained in the Announcement. Save as disclosed above, all information and contents set out in the Announcement remain unchanged. The Company wishes to apologize for any inconvenience caused to investors, and greatly appreciated for the kind understanding of investors.

By order of the Board
Tianjin TEDA Biomedical Engineering Company Limited
Sun Li
Chairman

Tianjin, the PRC
29 March 2018

As at the date of this announcement, the executive Directors of the Company are Sun Li, Hao Zhihui and Liu Renmu; the non-executive Directors of the Company are Cao Aixin, Feng Enqing, and Li Ximing; the independent non-executive Directors of the Company are Li Xudong, Wang Yongkang and Gao Chun.

This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the GEM website at <http://www.hkgem.com> on the “Latest Company Announcements” page for 7 days from the date of its posting, and it will also be published and remain on the website of the Company at www.bioteda.com.